Overview

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. - The name of the study drug involved in this study is: - Zafirlukast
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
National Institutes of Health (NIH)
Treatments:
Zafirlukast